Moxifloxacin: A respiratory fluoroquinolone

Marc Miravitlles, Antonio Anzueto

Research output: Contribution to journalArticle

22 Scopus citations

Abstract

Background: Respiratory quinolones are a class of antimicrobials with a high activity against most respiratory pathogens. Moxifloxacin is a fourth-generation fluoroquinolone that has been shown to be effective against Gram-positive, Gram-negative, and atypical strains, as well as multi-drug resistant Streptococcus pneumoniae. Objective: To review and update the clinical efficacy of moxifloxacin in the treatment of respiratory infections. Method: To perform a systematic review of publications on the clinical efficacy of moxifloxacin in respiratory infections. Results: The clinical efficacy of moxifloxacin has been shown in controlled studies of community-acquired pneumonia, exacerbations of chronic bronchitis and acute bacterial rhinosinusitis. Moxifloxacin has demonstrated a faster resolution of symptoms in community-acquired pneumonia and exacerbations of chronic bronchitis patients compared with first-line therapy together with excellent eradication rates. Conclusions: The use of moxifloxacin as first-line therapy for moderate to severe respiratory infections in the community and the hospital has been recognized in international guidelines.

Original languageEnglish (US)
Pages (from-to)1755-1772
Number of pages18
JournalExpert Opinion on Pharmacotherapy
Volume9
Issue number10
DOIs
StatePublished - Jul 1 2008

    Fingerprint

Keywords

  • Chronic bronchitis
  • Community-acquired pneumonia
  • Moxifloxacin
  • Quinolones
  • Rhinosinusitis

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this